Navigation Links
Neurochem to present at JPMorgan Healthcare Conference
Date:1/3/2008

LAVAL, QC, Jan. 3 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announces today that on Thursday, January 10, 2008, Dr. Francesco Bellini, Chairman, President and CEO, will present Neurochem's overall strategy at the 26th Annual JPMorgan Healthcare Conference to be held at the Westin St. Francis Hotel, in San Francisco (CA). The presentation will take place at 2:00 P.M. PST, in the Elizabethan A & B room.

About Neurochem

Neurochem Inc. is a global health company focused on the research, development and commercialization of products to provide innovative health solutions to patients suffering from serious diseases.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1-877-680-4500 or visit our Web Site at http://www.neurochem.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the Neurochem group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of Neurochem Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise. Please see the Annual Information Form of Neurochem Inc. for further risk factors that might affect the Neurochem group and its business.

For further information, please contact:

Lise Hebert, PhD Tel: (450) 680-4570

Vice President, Corporate Communications lhebert@neurochem.com


'/>"/>
SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Neurochem reports results for third quarter of fiscal 2007
2. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
3. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
4. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
5. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
6. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
7. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
8. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
9. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
10. AtriCure to Present at Roth Capital Partners 2007 New York Conference
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is ... natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO ... to create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... ... December 05, 2016 , ... The ... care facility – Avamere Transitional Care of Puget Sound ; located at ... health care center will provide patients recovering from illness or injury with intensive ...
(Date:12/5/2016)... VA (PRWEB) , ... December 05, 2016 , ... ... today announced it has been featured in SuperbCrew magazine, a leading online tech ... tech world. This interview, now featured on SuperbCrew.com, explores the state of enterprise ...
(Date:12/5/2016)... ... ... Researchers at Johns Hopkins All Children’s Hospital want to learn more about ... of three years, researchers will study concussions and changes in brain function by monitoring ... sensors, will track the location and force of the hit. The sensors store data ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy ... through tomorrow, December 6th, sparks a conversation about epilepsy, bearing down on the ... 26 people will be diagnosed with epilepsy within their lifetime. With such a ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Sanovas, Inc., a life science asset holding ... its wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed ... - http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed ...
(Date:12/5/2016)... 2016  CVS Health, the nation,s largest pharmacy innovation ... score of 100 percent on the Corporate Equality Index ... an annual national benchmarking survey and report on corporate ... the Human Rights Campaign Foundation. "Our ... colleagues, customers and suppliers bring to CVS Health," said ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 /PRNewswire/ ... announced preliminary safety and efficacy data from a ... selective MDM2 inhibitor, suggesting that DS-3032 may be ... acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome ... of the phase 1 study of DS-3032 were presented ...
Breaking Medicine Technology: